Circulating levels of ganglioside GM3 in metabolic syndrome: A pilot study

• Published in: Obesity research & clinical practice 2008-12, Vol.2 (4), p.231-238
• Main Authors: Sato, Takashige, Nihei, Yutaka, Nagafuku, Masakazu, Tagami, Seiichi, Chin, Rina, Kawamura, Mitsunobu, Miyazaki, Shigeru, Suzuki, Makoto, Sugahara, Shu-ichi, Takahashi, Yasuyuki, Saito, Atsuko, Igarashi, Yasuyuki, Inokuchi, Jin-ichi
• Format: Article
• Language: English
• Subjects: Endocrinology & Metabolism; Internal Medicine
• ISSN: 1871-403X
• DOI: 10.1016/j.orcp.2008.06.001

Summary Background Insulin resistance is a characteristic feature of metabolic syndrome. Ganglioside GM3 [α-Neu5Ac-(2-3)-β-Gal-(1-4)-β-Glc-(1-1)-ceramide] may impair insulin sensitivity in adipose tissue. We investigated the relationship between serum GM3 levels and adiposity indices, as well as between serum GM3 levels and metabolic risk variables. Methods Study 1: we assessed serum GM3 levels in normal subjects and in patients with hyperglycemia and/or hyperlipidemia (HL). Study 2: we investigated the relationship between serum GM3 levels and metabolic risk variables in patients with type 2 diabetes. Results Study 1: serum GM3 levels were higher in hyperglycemic patients (1.4-fold), hyperlipidemic patients (1.4-fold) and hyperglycemic patients with hyperlipidemia (1.6-fold), than in normal subjects. Study 2: serum GM3 levels were significantly increased in type 2 diabetic patients with severe obesity (visceral fat area (VFA) >200 cm2 , BMI > 30). The GM3 level was positively correlated with LDL-c (0.403, p = 0.012) in type 2 diabetes mellitus, but not affected by blood pressure. In addition, the high levels of small dense LDL (>10 mg/dL) were associated with the elevation of GM3. Conclusions Serum GM3 levels was affected by glucose and lipid metabolism abnormalities and by visceral obesity. GM3 may be a useful marker for severity of metabolic syndrome.